Non-Hodgkin Lymphoma
Conference Coverage
CAR exhibits activity in resistant B-cell malignancies
Photo courtesy of ASH ORLANDO, FL—Allogeneic chimeric antigen receptor (CAR) T cells directed against CD19 can have “significant” activity...
Conference Coverage
Ibrutinib ‘treatment of choice’ in rel/ref MCL
Annual Meeting Photo courtesy of ASH ORLANDO, FL—The BTK inhibitor ibrutinib should be considered the treatment of choice for patients with...
News
Trial of ofatumumab in FL stopped early
Photo courtesy of GSK Genmab A/S said it is stopping a phase 3 trial of ofatumumab in follicular lymphoma (FL) after a planned interim analysis...
News
ESRD treatments linked to different cancers
Photo by Anna Frodesiak Patients with end-stage renal disease (ESRD) may have different cancer risks according to the treatment they are...
News
Drug ‘life-changing’ for CLL patients in phase 1 trial
Photo courtesy of NIH A novel Bruton’s tyrosine kinase inhibitor has proven life-changing for patients with chronic lymphocytic leukemia (CLL) who...
News
Inhibitor exhibits ‘modest’ activity in lymphoma
A small-molecule inhibitor has shown modest anticancer activity in a phase 1 trial of patients with relapsed/refractory lymphoma or multiple...
Conference Coverage
Breast cancer drug may also work in MCL, myeloma
NEW YORK—Targeting the cell cycle with cyclin-dependent kinase (CDK) inhibitors may be an effective strategy to treat lymphoma and myeloma,...
News
FDA grants drug priority review as FL therapy
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologics license application for obinutuzumab (Gazyva)...
Conference Coverage
Post-ibrutinib management in MCL unclear, speaker says
NEW YORK—Despite an “unprecedented” single-agent response rate and progression-free survival (PFS) in previously treated mantle cell lymphoma (MCL...
Conference Coverage
Reprogramming the immune system
showing Hodgkin lymphoma NEW YORK—Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others...
Conference Coverage
Median DOR, PFS not yet reached for ibrutinib in CLL
NEW YORK—Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inhibitor...